APMDApnimed
Develops novel oral therapies targeting neuromuscular dysfunction in obstructive sleep apnea.
$16IPO price
$192MRaised
$25Day-1 close
78.44%Day-1 return
Develops novel oral therapies targeting neuromuscular dysfunction in obstructive sleep apnea.
Company description (source: StockAnalysis)
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
51CFO read: Requires CFO expertise in clinical-stage biopharma financial governance and FDA-path capital planning.
Management details per the SEC prospectus.
Does your company need this kind of CFO?
51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.
Talk to us